Kamada Ltd. has announced the launch of two new biosimilar products in Israel, marking a significant expansion of its portfolio. This move is expected to enhance the company's revenue stream, projecting approximately $10 million in annual revenue by 2028 and between $20 million to $25 million by 2030. The introduction of these biosimilars is a strategic effort to solidify Kamada's position in the biopharmaceutical market.
About Kamada Ltd.
Kamada Ltd. is a global biopharmaceutical company that specializes in developing and marketing products for rare and serious conditions. The company operates under the SIC code 2834, which pertains to pharmaceutical preparations. Kamada is listed on the Nasdaq under the ticker symbol KMDA and is categorized as an accelerated filer. The company is headquartered in Rehovot, Israel.
What the Filing Says
According to the recent filing, Kamada has launched two new biosimilar products: Ustekinumab-Kamada, a biosimilar to Stelara®, and Enoxaparin-Kamada, a biosimilar to Clexane®. The company stated, "The growth of our biosimilar product portfolio is one of our key strategic growth pillars." This expansion adds to their existing biosimilar offerings, which include Bevacizumab-Kamada and Pegfilgrastim-Kamada.
Impact
The launch of these new biosimilars is expected to have a positive impact on Kamada's financial performance. The company anticipates that its biosimilar portfolio will generate around $4 million in sales for 2026, with significant growth projected in the following years. This expansion may also influence competitors in the pharmaceutical preparations sector, as more companies may look to enter the biosimilars market.
What's Next
Kamada plans to continue its growth strategy by evaluating additional licensing opportunities and expects to launch at least two more biosimilar products in 2027. The filing does not specify any immediate next steps beyond these plans.